)
Sophia Bardehle
Discovery Research Lead,
Cerevel
Dr. Sophia Bardehle is a program and team lead at Cerevel Therapeutic. As in vivo pharmacology functional lead she oversees preclinical models and biomarker development for several early programs for neuropsychiatric, as well as neuro-degenerative and -immune conditions. Dr. Sophia Bardehle earned her PhD from the LMU in Munich, Germany, where she studied astrogliosis after TBI using 2p microscopy. As a postdoc at the Gladstone Institute for Neurological Disease in San Francisco, Dr. Bardehle investigated innate immune mechanisms in MS models. Before joining Cerevel in 2021, Dr. Bardehle led multiple cross-functional discovery projects focused on neuroimmune targets in AD within the Neuroscience team at Merck in Boston.